Becton, Dickinson and Company (BDXA)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Becton, Dickinson and Company (BDXA) trades at $59.24 with AI Score 45/100 (Grade C). Becton, Dickinson and Company (BDXA) is a global medical technology company that develops, manufactures, and sells a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. Market cap: $55.91B, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for BDXA: BDXA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BDXA against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BDXA: the 1 perspectives are evenly split.
How is this calculated? →Becton, Dickinson and Company (BDXA) Healthcare & Pipeline Overview
Becton, Dickinson and Company (BDXA) is a leading global medical technology company, distinguished by its comprehensive portfolio of medical supplies, devices, and diagnostic products. With a market capitalization of $55.91B, BDXA serves diverse healthcare segments, emphasizing innovation and quality in a competitive medical instruments and supplies sector.
What Is the Investment Thesis for BDXA?
Becton, Dickinson and Company (BDXA) presents a compelling investment case based on its established market position, diverse product portfolio, and consistent profitability. With a market capitalization of $55.91B and a P/E ratio of 36.5, BDXA demonstrates financial stability. The company's 8.0% profit margin and 45.8% gross margin highlight operational efficiency. Growth catalysts include expanding its presence in emerging markets and introducing innovative medical technologies. Potential risks include increasing competition and regulatory changes. The dividend yield of 2.17% offers an additional incentive for investors. BDXA's commitment to innovation and strategic acquisitions positions it for sustained growth in the healthcare sector.
Based on FMP financials and quantitative analysis
BDXA Key Highlights
- Market capitalization of $55.91B reflects BDXA's significant presence in the medical technology industry.
- P/E ratio of 36.5 indicates investor confidence in BDXA's earnings potential.
- Profit margin of 8.0% demonstrates effective cost management and profitability.
- Gross margin of 45.8% highlights BDXA's ability to maintain competitive pricing and efficient production.
- Dividend yield of 2.17% provides a steady income stream for investors.
Who Are BDXA's Competitors?
BDXA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AKYA Akoya Biosciences, Inc. | $1.29 | -5.15% | $64.44M | 50 |
| COR Cencora, Inc. | $297.55 | +0.35% | $57.89B | 74 |
| NYXH Nyxoah S.A. | $1.75 | +1.74% | $69.31M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $27.70 | +2.67% | $1.62B | 67 |
| STXS Stereotaxis, Inc. | $1.88 | +5.03% | $183.74M | 60 |
| IVTY Invuity, Inc. | $7.39 | +0.00% | 60 | |
| FSPKF Fisher & Paykel Healthcare Corporation Limited | $22.52 | +0.00% | $13.23B | 51 |
| CZMWY Carl Zeiss Meditec AG | $32.76 | +3.56% | $2.87B | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BDXA's Key Strengths?
- Strong brand reputation and established market presence.
- Diverse product portfolio with a wide range of medical devices and supplies.
- Extensive distribution network and global reach.
- Significant investment in research and development, leading to innovative products.
What Are BDXA's Weaknesses?
- Exposure to regulatory changes and compliance requirements.
- Dependence on key suppliers and potential supply chain disruptions.
- Intense competition from other medical technology companies.
- Potential for product recalls and liability claims.
What Could Drive BDXA Stock Higher?
- Launch of new diagnostic platforms in Q3 2026, expected to drive revenue growth in the diagnostic systems segment.
- Expansion of digital health solutions, creating new revenue streams and strengthening relationships with healthcare providers.
- Strategic acquisitions to expand product portfolio and geographic reach, enhancing BDXA's competitive position.
- Partnerships and collaborations to accelerate innovation and market access, leveraging external expertise and resources.
What Are the Key Risks for BDXA?
- Rich valuation — a P/E of 36.5 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Insider selling — insiders were net sellers of roughly $3.0M recently.
- Increasing competition from established and emerging players, potentially impacting market share and profitability.
- Pricing pressures from healthcare providers and payers, requiring BDXA to optimize its cost structure.
- Economic downturns and reduced healthcare spending, potentially affecting demand for medical devices and supplies.
- Technological obsolescence and the need for continuous innovation, requiring continuous investment in research and development.
- Regulatory changes and compliance requirements, potentially increasing costs and delaying product approvals.
What Are the Growth Opportunities for BDXA?
- Expansion in Emerging Markets: BDXA has a significant opportunity to expand its presence in emerging markets, particularly in Asia and Latin America. These regions are experiencing rapid growth in healthcare spending, driven by increasing populations and improving access to healthcare services. By tailoring its product offerings to meet the specific needs of these markets, BDXA can capture a larger share of the global medical technology market. The emerging markets healthcare sector is projected to grow at a CAGR of 8-10% over the next five years.
- New Product Development: BDXA can drive growth through continuous innovation and the development of new medical technologies. Investing in research and development to create advanced diagnostic tools, drug delivery systems, and other medical devices will enable BDXA to address unmet medical needs and gain a competitive advantage. The company's focus on innovation aligns with the industry trend towards personalized medicine and minimally invasive procedures. The global market for new medical technologies is estimated at $150 billion annually.
- Strategic Acquisitions: BDXA can pursue strategic acquisitions to expand its product portfolio and geographic reach. Acquiring companies with complementary technologies or market access can accelerate BDXA's growth and enhance its competitive position. The company has a history of successful acquisitions, and this strategy remains a key driver of its growth. The medical technology industry is highly fragmented, providing ample opportunities for consolidation.
- Digital Health Solutions: BDXA can leverage digital health technologies to enhance its product offerings and improve patient outcomes. Developing digital platforms for remote patient monitoring, data analytics, and telehealth can create new revenue streams and strengthen BDXA's relationships with healthcare providers. The digital health market is experiencing rapid growth, driven by the increasing adoption of telemedicine and the need for more efficient healthcare delivery. The global digital health market is projected to reach $379 billion by 2024.
- Partnerships and Collaborations: BDXA can collaborate with other companies and research institutions to accelerate innovation and expand its market reach. Partnering with pharmaceutical companies, biotechnology firms, and academic centers can provide access to new technologies, expertise, and markets. Collaborative efforts can also help BDXA address complex healthcare challenges and develop comprehensive solutions. Strategic partnerships are increasingly important in the medical technology industry, as companies seek to leverage each other's strengths and resources.
What Opportunities Does BDXA Have?
- Expansion in emerging markets with growing healthcare spending.
- Development of new medical technologies and digital health solutions.
- Strategic acquisitions to expand product portfolio and geographic reach.
- Partnerships and collaborations to accelerate innovation and market access.
What Threats Does BDXA Face?
- Increasing competition from established and emerging players.
- Pricing pressures from healthcare providers and payers.
- Economic downturns and reduced healthcare spending.
- Technological obsolescence and the need for continuous innovation.
What Are BDXA's Competitive Advantages?
- Strong brand reputation and established market presence.
- Diverse product portfolio with a wide range of medical devices and supplies.
- Extensive distribution network and global reach.
- Significant investment in research and development, leading to innovative products.
- Stringent regulatory approvals and high barriers to entry in the medical technology industry.
What Does BDXA Do?
Founded in 1897, Becton, Dickinson and Company (BDXA) has evolved into a global medical technology leader. Initially focused on manufacturing medical devices, BDXA expanded its portfolio to include a wide array of products and services spanning medical supplies, laboratory equipment, and diagnostic solutions. The company's evolution reflects a commitment to advancing healthcare through innovation and strategic acquisitions. BDXA's products are used in healthcare settings, research laboratories, and by individuals worldwide. Key product categories include medication delivery solutions, diagnostic systems, and biosciences products. BDXA operates globally, with a significant presence in North America, Europe, and Asia. The company competes with other major players in the medical technology industry, focusing on delivering high-quality, reliable products and solutions to improve patient outcomes and healthcare efficiency. BDXA's commitment to research and development drives its ability to introduce innovative products and maintain a competitive edge in the rapidly evolving healthcare landscape.
What Products and Services Does BDXA Offer?
- Develops and manufactures medical devices and supplies.
- Provides diagnostic systems for clinical laboratories.
- Offers biosciences products for research and drug discovery.
- Delivers medication delivery solutions for hospitals and clinics.
- Provides products for specimen management.
- Offers surgical instruments and solutions.
- Develops products for diabetes care.
How Does BDXA Make Money?
- Develops and manufactures a wide range of medical devices and supplies.
- Sells products directly to healthcare providers, research institutions, and consumers.
- Generates revenue through product sales and related services.
- Invests in research and development to create innovative products.
What Industry Does BDXA Operate In?
Becton, Dickinson and Company operates within the medical instruments and supplies industry, a sector characterized by continuous innovation and increasing demand for advanced healthcare solutions. The global medical devices market is projected to reach $600 billion by 2028, driven by an aging population, rising prevalence of chronic diseases, and technological advancements. BDXA competes with companies like AKYA, AVGR, COR, GMVD, and IVC, focusing on delivering high-quality, reliable products and solutions. The industry is subject to stringent regulatory requirements and intense competition, requiring companies to invest heavily in research and development to maintain a competitive edge.
Who Are BDXA's Key Customers?
- Hospitals and clinics
- Clinical laboratories
- Research institutions
- Pharmaceutical companies
- Individual patients
Net buyingInsider Activity
Over the past six months, Becton, Dickinson and Company insiders filed 13 SEC Form 4 transactions — 7 sales and 6 purchases. On net that is roughly 2K shares acquired (about $3.0M) — insiders putting money in tends to read as conviction.
Quarterly Financial Performance: Becton, Dickinson and Company
Revenue for Becton, Dickinson and Company came in at $4.71B during Q1 2026, a 10.2% contraction versus the preceding quarter. The company recorded a net loss of $311.0M, with diluted EPS of $-1.11. Revenue has contracted over three consecutive quarters, which investors in this large-cap Healthcare stock should monitor closely. Across the four most recent quarters, BDXA averaged $0.99 in diluted EPS.
BDXA Valuation & Market Position
With a $55.91B market cap, Becton, Dickinson and Company sits in the large-cap segment of the market. Relative to its peer group, BDXA's quantitative score of 45/100 is below the peer average of 64/100.
ROE 5%Key Financial Metrics
Return on equity for Becton, Dickinson and Company stands at 4.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.2%, showing how much profit it generates from its asset base. BDXA trades at a trailing price-to-earnings ratio of 36.46, above the Healthcare sector average of ~23x. Its free cash flow yield is 5.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.94 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 2.7%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 7/9Financial Health
Becton, Dickinson and Company's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.12 places it in the grey zone, a middle ground that warrants monitoring.
Company Profile
Becton, Dickinson and Company operates in the Medical - Instruments & Supplies industry within the Healthcare sector. BDXA has traded publicly since 2017.
BDXA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Strong brand reputation and established market presence.
- Diverse product portfolio with a wide range of medical devices and supplies.
- Extensive distribution network and global reach.
- Significant investment in research and development, leading to innovative products.
Bear Case
- Exposure to regulatory changes and compliance requirements.
- Dependence on key suppliers and potential supply chain disruptions.
- Intense competition from other medical technology companies.
- Potential for product recalls and liability claims.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $4.71B | -$311M | -$1.11 |
| Q4 2025 | $5.25B | $382M | $1.34 |
| Q3 2025 | $5.89B | $493M | $1.72 |
| Q2 2025 | $5.51B | $574M | $2.00 |
Based on FMP financials and quantitative analysis
BDXA Latest News
No recent news available for BDXA.
BDXA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BDXA.
Price Targets
Wall Street price target analysis for BDXA.
BDXA MoonshotScore
What does this score mean?
The MoonshotScore rates BDXA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
What Investors Ask About Becton, Dickinson and Company (BDXA) — Healthcare
What does Becton, Dickinson and Company do?
Becton, Dickinson and Company (BDXA) is a global medical technology company that develops, manufactures, and sells a wide range of medical devices, diagnostic systems, and biosciences products. The company's products are used in healthcare settings, research laboratories, and by individuals worldwide. BDXA's key business segments include medical, life sciences, and interventional. The company focuses on providing innovative solutions to improve patient outcomes, enhance healthcare efficiency, and advance scientific research. BDXA operates globally, with a significant presence in North America, Europe, and Asia.
What do analysts say about BDXA stock?
Analyst consensus on BDXA stock is generally positive, reflecting the company's strong market position, diverse product portfolio, and consistent financial performance. Key valuation metrics include a P/E ratio of 36.5 and a dividend yield of 2.17%. Growth considerations include BDXA's expansion in emerging markets, new product development, and strategic acquisitions. Analysts also note potential risks, such as increasing competition and regulatory changes. Overall, analysts view BDXA as a stable and reliable investment in the healthcare sector, with the potential for long-term growth.
What are the main risks for BDXA?
The main risks for Becton, Dickinson and Company (BDXA) include increasing competition from other medical technology companies, pricing pressures from healthcare providers and payers, and potential regulatory changes. The company also faces risks related to product recalls, liability claims, and supply chain disruptions. Additionally, BDXA's reliance on innovation and new product development exposes it to the risk of technological obsolescence. Economic downturns and reduced healthcare spending could also negatively impact demand for BDXA's products and services. Effective risk management is crucial for BDXA to maintain its competitive position and achieve its growth objectives.
What revenue streams does Becton, Dickinson and Company have in healthcare?
Becton, Dickinson and Company's revenue streams are diversified across several product lines, therapeutic areas, and geographic markets within the healthcare sector. Key revenue streams include sales of medical devices and supplies, diagnostic systems, and biosciences products. By therapeutic area, BDXA generates revenue from products used in medication delivery, diabetes care, and infection prevention. Geographically, North America and Europe are significant revenue contributors, with growing contributions from emerging markets in Asia and Latin America. This diversification helps mitigate risks and provides a stable revenue base for BDXA.
How does Becton, Dickinson and Company manage patent expiration risks?
Becton, Dickinson and Company manages patent expiration risks through a combination of strategies, including continuous innovation, patent portfolio management, and lifecycle management. The company invests heavily in research and development to create new and improved products, extending the lifecycle of its existing product lines. BDXA also actively monitors its patent portfolio, seeking to protect its intellectual property and defend against infringement. Furthermore, the company employs lifecycle management strategies, such as developing new formulations or delivery methods for existing drugs, to mitigate the impact of patent expirations and maintain market share. This proactive approach helps BDXA sustain its competitive advantage and protect its revenue streams.
What are the key factors to evaluate for BDXA?
Becton, Dickinson and Company (BDXA) holds an AI score of 45/100 (low). P/E: 36.5x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does BDXA data refresh on this page?
BDXA prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BDXA's recent stock price performance?
Becton, Dickinson and Company (BDXA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong brand reputation and established market presence. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for BDXA. The information provided is based on available data and may be subject to change.
- Financial data is based on the most recent filings and may not reflect current market conditions.